Olanzapine, an antipsychotic medication, may help cancer patients increase their appetite and gain weight, according to a 2026 systematic review of 18 studies published in Discover Oncology. Gram Research analysis found that 10 out of 14 studies reported increased appetite when patients took olanzapine at doses of 2.5-10 mg daily, and weight gain occurred in patients taking the drug for 8-12 weeks. However, most studies weren’t specifically designed to test appetite improvement, and only two were high-quality, so doctors need more rigorous research before widely recommending it for cancer-related appetite loss.
Cancer patients often struggle to eat and lose dangerous amounts of weight, a problem called cachexia. Researchers reviewed 18 studies on olanzapine, a medication originally used for psychiatric conditions, to see if it could help cancer patients regain their appetite and gain weight. According to Gram Research analysis, olanzapine appeared to increase appetite in most studies and caused weight gain in some patients. However, the research quality was mixed, and most studies weren’t specifically designed to test this use. Scientists say more rigorous testing is needed before doctors can confidently recommend olanzapine for cancer-related appetite loss.
Key Statistics
A 2026 systematic review of 18 studies in Discover Oncology found that olanzapine increased appetite in 10 out of 14 studies where appetite was measured in cancer patients taking doses of 2.5-10 mg daily for 3 days to 12 weeks.
According to research reviewed by Gram, weight gain with olanzapine was documented in two randomized controlled trials of cancer patients taking 2.5-5 mg daily for 8-12 weeks, though most studies were not designed primarily to measure weight change.
Only 2 out of 14 randomized controlled trials in the systematic review were judged to be at low risk of bias, indicating substantial methodological limitations in the current evidence for olanzapine’s appetite-stimulating effects in cancer patients.
The Quick Take
- What they studied: Whether olanzapine, a medication that can increase appetite, helps cancer patients eat more and gain weight
- Who participated: 18 studies involving cancer patients of various ages and types, though most studies weren’t originally designed to test appetite improvement
- Key finding: Olanzapine appeared to increase appetite in 10 out of 14 studies where appetite was measured, and caused weight gain in some patients taking it for 8-12 weeks
- What it means for you: Olanzapine might help cancer patients struggling with appetite loss, but doctors need more high-quality research before widely recommending it for this purpose. Talk to your oncologist about whether it could be right for you.
The Research Details
Researchers searched three major medical databases (PubMed, Embase, and Cochrane Library) for all studies testing olanzapine in cancer patients. They found 1,733 potentially relevant studies and carefully reviewed 79 of them in detail. Ultimately, 18 studies met their criteria: 14 randomized controlled trials (the gold standard where patients randomly receive either the drug or a placebo), one prospective study (following patients forward in time), and three retrospective studies (looking back at patient records).
The researchers looked at whether olanzapine increased appetite and caused weight gain. They also rated how reliable each study was using standard scientific tools. This approach, called a systematic review, helps scientists combine information from many studies to see the big picture.
Most individual studies on olanzapine in cancer patients weren’t designed to test appetite improvement—they were studying it for other reasons like reducing nausea from chemotherapy. By systematically reviewing all available evidence together, researchers could see whether appetite improvement was a consistent side effect worth investigating further. This type of review helps doctors and patients understand what the current evidence actually shows.
The review found significant quality problems. Only 2 out of 14 randomized trials were considered high-quality (low risk of bias). Most studies had concerns about their design or execution. The observational studies (which just watched what happened without controlling conditions) had serious reliability problems. Studies used different doses of olanzapine (2.5-10 mg daily), treated patients for different lengths of time (3 days to 12 weeks), and measured appetite differently. These differences make it harder to draw firm conclusions.
What the Results Show
Increased appetite was the most commonly reported benefit. Ten out of 14 studies that measured appetite found that olanzapine increased how much patients wanted to eat. Patients took doses ranging from 2.5 to 10 milligrams daily for periods lasting from 3 days to 12 weeks.
Weight gain was less consistently reported. Only two randomized controlled trials specifically measured weight change, and both found that patients gained weight when taking olanzapine 2.5-5 mg daily for 8-12 weeks. However, most studies didn’t set out to measure weight as a primary goal—weight changes were often noted as a side effect while researchers were studying olanzapine for other purposes.
The appetite improvements appeared across different types of cancer and patient ages, suggesting the effect might be fairly broad. However, because most studies weren’t designed specifically to test appetite improvement, these findings came from secondary analyses rather than carefully planned experiments.
The review noted that olanzapine’s appetite-stimulating effects appeared relatively quickly in some studies—within days to weeks of starting treatment. The medication was generally well-tolerated in cancer patients, though the review didn’t comprehensively evaluate side effects. Some studies mentioned that patients experienced other olanzapine side effects like drowsiness, but detailed safety information wasn’t the focus of this review.
This is the first systematic review specifically examining olanzapine for appetite and weight in cancer patients. Previous research has shown that olanzapine reliably increases appetite and weight in psychiatric patients and other populations. This review confirms that the appetite-stimulating effect appears to carry over to cancer patients, but the evidence is weaker because most cancer studies weren’t designed with this outcome in mind. The findings align with olanzapine’s known pharmacological properties but highlight the need for cancer-specific research.
The biggest limitation is that most studies weren’t designed to test appetite improvement—they were studying olanzapine for other reasons, so appetite data came from secondary analyses that may not have been carefully measured. Different studies used different doses and treatment durations, making comparisons difficult. Only two studies were high-quality randomized trials. The review couldn’t determine the optimal dose or how long patients should take olanzapine. Most studies were small, and some had significant design flaws. The heterogeneity (differences between studies) was substantial, meaning you can’t simply add up results to get one clear answer.
The Bottom Line
Based on current evidence (moderate confidence): Olanzapine may be considered as a potential option for cancer patients with severe appetite loss, particularly when other approaches haven’t worked. Typical doses studied were 2.5-5 mg daily. However, this should only be done under close medical supervision. Low confidence: We cannot yet recommend olanzapine as a first-line treatment for cancer-related appetite loss. High-quality research is needed before making that recommendation.
Cancer patients experiencing significant appetite loss and weight loss (cachexia) should discuss olanzapine with their oncologist. Patients already taking olanzapine for other reasons (like managing chemotherapy nausea) may benefit from its appetite-stimulating effects. This is less relevant for patients with normal appetite or those who cannot tolerate antipsychotic medications. People with certain medical conditions (heart problems, diabetes, or movement disorders) should discuss risks with their doctor.
Based on the studies reviewed, appetite improvements appeared within days to weeks of starting olanzapine. Weight gain typically took 8-12 weeks to become noticeable. However, individual responses vary, and more research is needed to establish realistic timelines.
Frequently Asked Questions
Does olanzapine help cancer patients gain weight?
Olanzapine may help cancer patients gain weight, according to a 2026 systematic review. Two high-quality studies found weight gain in patients taking 2.5-5 mg daily for 8-12 weeks. However, most research wasn’t specifically designed to measure weight, so more rigorous testing is needed.
What dose of olanzapine is used to increase appetite in cancer patients?
Studies reviewed used olanzapine doses ranging from 2.5 to 10 mg daily. The two studies showing weight gain used lower doses of 2.5-5 mg daily. Your oncologist should determine the appropriate dose based on your individual situation and other medications.
How quickly does olanzapine increase appetite?
Some studies reported appetite improvements within days to weeks of starting olanzapine. Weight gain typically took 8-12 weeks to become noticeable. Individual responses vary, and your doctor can monitor your progress with regular check-ins.
Is olanzapine safe for cancer patients with appetite loss?
Olanzapine was generally well-tolerated in the cancer studies reviewed, though the systematic review didn’t comprehensively evaluate side effects. Discuss potential risks and benefits with your oncologist, especially if you have heart problems, diabetes, or movement disorders.
Should I ask my doctor about olanzapine for cancer-related appetite loss?
It’s reasonable to discuss olanzapine with your oncologist if you’re experiencing severe appetite loss and weight loss. Current evidence suggests it may help, but it’s not yet a standard first-line treatment. Your doctor can assess whether it’s appropriate for your specific situation.
Want to Apply This Research?
- If taking olanzapine for appetite, track daily food intake (number of meals/snacks completed), appetite rating (1-10 scale), and weekly weight. Log these metrics every morning to monitor trends over 4-week periods.
- Set a reminder to weigh yourself weekly at the same time of day. Take photos of meals to visually track eating patterns. Use the app to set small, achievable eating goals (e.g., ‘complete 3 meals today’) and celebrate when you hit them.
- Create a 12-week tracking dashboard showing appetite trends, weight trajectory, and meal completion rates. Share monthly summaries with your oncology team to assess whether olanzapine is working and whether dose adjustments are needed. Flag any concerning side effects (excessive drowsiness, blood sugar changes) for immediate discussion with your doctor.
This article summarizes research on olanzapine for appetite and weight in cancer patients but is not medical advice. Olanzapine is an antipsychotic medication with potential side effects and drug interactions. Do not start, stop, or change olanzapine without consulting your oncologist or primary care physician. The evidence reviewed is preliminary, with most studies not specifically designed to test appetite improvement. Individual responses vary significantly. This information is for educational purposes and should not replace professional medical evaluation and personalized treatment recommendations from your healthcare team.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.